MDSpire - Takeaway
Conference News

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...

Share

  • 1

    Pelabresib combined with ruxolitinib shows significant spleen volume reduction.

  • 2

    Elritercept reduces anemia and improves symptoms in poor-prognosis MF patients.

  • 3

    Ruxolitinib treatment can lead to long-term benefits and transfusion independence.

  • 4

    Stem cell transplantation is the only curative treatment for higher-risk MF patients.

  • 5

    New agents targeting CALR mutations show promise in previously unresponsive patients.

Original Source(s)

ASH 2025: Myelofibrosis Roundup

  • by Caroline Helwick

  • March 24, 2026

Related Content

Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precurso...

POEMS Syndrome: Diagnostic Clues From Neuropathy to Bone Marrow Findings

POEMS syndrome is a poorly understood and complex paraneoplastic plasma cell disorder characterized by peripheral neuropathy and multisystem involvement, including organomegaly, endocrinopathy, monocl...

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...